<DOC>
	<DOC>NCT01650077</DOC>
	<brief_summary>Non-interventional study consisting of a population of patients who had received for soft tissue sarcoma by at least 2 courses of Yondelis® at a dose of 1.5 mg / m² / 3 weeks after failure or intolerance to doxorubicin / ifosfamide from 2007 to 2011.</brief_summary>
	<brief_title>Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria</brief_title>
	<detailed_description>Patient selection is based on a database of retrospectively within the GSF / GETO. The tumor assessment must be made by scanner at baseline and post-C2 or C3 and should be available and sent to sponsor. The comparative reading of the imaging is centralized and made without the knowledge of the local assessment: - sum of the large diameter for 2 imagery (baseline and 1st evaluation - tumor density on areas of interest for the 2 imaging (baseline and 1st evaluation - Rank patients according to two methods (Choi and RECIST): complete response, partial response, stability, progress and non-assessable.</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>age ≥ 18 years locally advanced or metastatic soft tissue sarcoma treated with Yondelis after failure or intolerance to doxorubicin/ifosfamide treated between 2007 and 2011 have had at least 2 cycles of Yondelis assessment of tumor by CT scan (baseline and after 2 or 3 cycles of Yondelis) Gastro Intestinal Stromal Tumor GIST primitive bone sarcoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Intolerance to doxorubicin/ifosfamide</keyword>
	<keyword>CHOI criteria</keyword>
</DOC>